We have compared the therapeutic activity of IL-12 and IL-18 in mice carryi
ng IL-2 gene-transduced syngeneic sarcoma Mc12. The IL-2 gene-transduced sa
rcoma has previously been utilized as an irradiated, genetically modified t
umour vaccine. Murine recombinant IL-12 was capable of suppressing growth o
f the IL-2 gene-modified sarcoma Mc12 in syngeneic mice more efficiently th
an growth of the parental Mc12 sarcoma. In contrast, murine recombinant IL-
18 could neither inhibit growth of the parental Mc12 sarcoma, nor suppress
growth of its IL-2 gene-modified transfectant. These results suggest that a
lthough both of these cytokines are functionally related and participate in
the induction of IFN gamma production as well as in cell-mediated immune c
ytotoxicity, in the murine sarcoma system only IL-12 is therapeutically act
ive and exerts its therapeutic effect in concert with the IL-2 gene. Thus,
intratumoral IL-2 gene transfer improves the therapeutic efficacy of IL-12;
administration of recombinant IL-12 should therefore be considered as adju
vant in IL-2 gene therapy with irradiated, genetically modified tumour vacc
ines.